loading page

COVID-19 in Severe Asthma Network in Italy (SANI) patients: clinical features, impact of comorbidities and treatments
  • +14
  • Enrico HefflerOrcid,
  • Caterina DetorakiOrcid,
  • Marco Contoli,
  • Alberto Papi,
  • Giovanni Paoletti,
  • Giacomo Malipiero,
  • Luisa Brussino,
  • Claudia Crimi,
  • Daniela Morrone,
  • Marianna Padovani,
  • Giuseppe Guida,
  • Alberto Giovanni GerliOrcid,
  • stefano centanni,
  • Gianenrico Senna,
  • Pierluigi Paggiaro,
  • Francesco Blasi,
  • Giorgio Walter Canonica
Enrico Heffler
Orcid
Humanitas University
Author Profile
Caterina Detoraki
Orcid
Azienda Ospedaliera Universitaria Federico II, Naples, Italy
Author Profile
Marco Contoli
University of Ferrara
Author Profile
Alberto Papi
University of Ferrara
Author Profile
Giovanni Paoletti
Humanitas Clinical and Research Center
Author Profile
Giacomo Malipiero
Humanitas Clinical and Research Hospital, IRCCS
Author Profile
Luisa Brussino
University of Torino & AO Mauriziano
Author Profile
Claudia Crimi
University of Catania - AOU "Policlinico - Vittorio Emanuele"
Author Profile
Daniela Morrone
Severe Asthma Network in Italy (SANI) infrastructure
Author Profile
Marianna Padovani
University of Ferrara
Author Profile
Giuseppe Guida
Azienda Ospedaliera S Croce e Carle Cuneo
Author Profile
Alberto Giovanni Gerli
Orcid
2. Management Engineering Tourbillon Tech srl
Author Profile
stefano centanni
University of Milan
Author Profile
Gianenrico Senna
Verona University Hospital
Author Profile
Pierluigi Paggiaro
University of Pisa
Author Profile
Francesco Blasi
UniversitĂ  degli Studi di Milano, IRCCS Fondazione Ospedale Maggiore CĂ  Granda, Milan
Author Profile
Giorgio Walter Canonica
Humanitas Clinical and Research Center
Author Profile

Abstract

BACKGROUND: COronaVIrus Disease 19 (COVID-19) pandemic is affecting almost the entire world since February 2020. Patients with chronic pulmonary diseases, such as asthma and chronic obstructive lung disease potentially and theoretically may be more vulnerable and therefore seriously ill if infected by SARS-CoV-2; however, according to the first epidemiological studies published so far, chronic pulmonary diseases are under-reported. No data is available, so far, about the incidence of COVID-19 in severe asthmatics and about which are the COVID-19 outcomes in this subgroup of patients. METHODS:: In this study, we investigated the incidence of COVID-19 cases in a large population of severe asthmatics in Italy, describing their clinical characteristics and clinical course of COVID-19 disease. RESULTS: Twenty-six (1.73%) out of 1504 severe asthmatics were identified as confirmed or highly suspect with COVID-19. Nine (34.6%) of infected patients experienced worsening of asthma during the COVID-19 symptomatic period. Severe asthmatics affected by COVID-19, compared to those who did not contracted the infection, had a significantly higher prevalence of non-insulin-dependent diabetes mellitus (NIDDM) (15.4% vs 3.8%, p=0.002); among COVID-19 patients the proportion of those treated anti-IL5 biologic agents was higher (71%) compared to the number of patients treated with anti-IgE (29%). CONCLUSIONS: In our large cohort of severe asthmatics, the incidence of COVID-19 was particularly low, with higher prevalence of NIDDM as comorbidity, suggesting that NIDDM might be a risk factor for COVID-19 in severe asthmatics.